Takeda unveils secondary endpoint data from Phase III PsO pill trials

The key secondary endpoints found the PsO pill to be beneficial in high-impact areas, including the scalp, palms, and soles.

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a ...